Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.64 |
| ▸ | DRD1 | P21728 | 3/20 | 0.64 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD5 | P21918 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153999 | 0.89 | MAOA (0.57) | DRD2DRD1MAOAMAOBDRD3 | |
| SCHEMBL31841937 | 0.89 | MAOA (0.57) | DRD2DRD1MAOAMAOBDRD3 | |
| SCHEMBL1960377 | 0.82 | DRD2 (0.55) | DRD2DRD1DRD4DRD5MAOA | |
| SCHEMBL3246920 | 0.77 | MAOA (0.59) | MAOAMAOBDRD3 | |
| SCHEMBL13487187 | 0.77 | MAOA (0.59) | MAOAMAOBDRD3 | |
| SCHEMBL7645219 | 0.77 | DRD2 (0.55) | DRD2DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL10734704 | 0.77 | DRD1 (0.58) | DRD2DRD1DRD4DRD3SETD7 | |
| SCHEMBL10882588 | 0.77 | ADRA2A (0.69) | DRD2DRD1DRD4DRD5 | |
| SCHEMBL162670 | 0.76 | MAOA (0.46) | DRD2DRD1DRD4DRD5MAOA | |
| SCHEMBL1905994 | 0.76 | DRD2 (0.54) | DRD2DRD1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | DRD2 405/4885DRD1 1382/4885DRD4 528/4885 |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | DRD2 2011/4885DRD1 1438/4885DRD4 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.